NRXP

NRX Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders, specifically targeting unmet medical needs in suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). The company is advancing its lead product, NRX-100, a preservative-free intravenous ketamine formulation, for which it has filed an Abbreviated New Drug Application (ANDA) and is pursuing a New Drug Application (NDA). NRX operates primarily in the United States, leveraging clinical research to address critical mental health challenges.